T. Rowe Price Associates
CGON icon

T. Rowe Price Associates’s CG Oncology CGON Stock Holding History

T. Rowe Price Associates’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$270M Buy
3,805,010
+152,030
+4% +$9.94M 0.03% 426
2026
Q1 		$247M Buy
3,652,980
+209,836
+6% +$11.9M 0.03% 408
2025
Q4 		$143M Buy
3,443,144
+1,854,386
+117% +$76.7M 0.02% 554
2025
Q3 		$64M Sell
1,588,758
-424,932
-21% -$12.4M 0.01% 722
2025
Q2 		$52.4M Buy
2,013,690
+999,094
+98% +$24.1M 0.01% 724
2025
Q1 		$24.8M Buy
1,014,596
+69,402
+7% +$1.95M ﹤0.01% 897
2024
Q4 		$27.1M Buy
945,194
+353,787
+60% +$12.1M ﹤0.01% 919
2024
Q3 		$22.3M Sell
591,407
-73,738
-11% -$2.59M ﹤0.01% 973
2024
Q2 		$21M Sell
665,145
-326,973
-33% -$11.3M ﹤0.01% 955
2024
Q1 		$43.6M Buy
+992,118
New +$40.5M 0.01% 766

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates's CGON Position: Q2 2026 in Review

T. Rowe Price Associates increased its CG Oncology (CGON) stake by 4.2% in Q2 2026, buying an estimated $9.94M and bringing the position to 3,805,010 shares worth $270M. The position accounts for 0.03% of the portfolio, ranked #426.

T. Rowe Price Associates first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • T. Rowe Price Associates held 3,805,010 shares of CG Oncology worth $270M as of Q2 2026.
  • T. Rowe Price Associates bought 152,030 CG Oncology shares in Q2 2026, an estimated $9.94M.
  • CG Oncology made up 0.03% of T. Rowe Price Associates's portfolio in Q2 2026, its #426 holding.
  • T. Rowe Price Associates first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.